Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🚫 This provider appears on the OIG List of Excluded Individuals/Entities (LEIE)
Exclusion type: 1128b3 · Date: 20240820 · State: PA
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
4,837
Total Claims
$592K
Drug Cost
412
Beneficiaries
$1,437
Cost/Patient
Risk Score Breakdown 35/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-88%
Opioid rate vs peers
0.3% vs 2.6% avg
+35%
Cost per patient vs peers
$1,437 vs $1,068 avg
+78%
Brand preference vs peers
16.0% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
0.3%
Opioid Rate
15
Opioid Claims
$114
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 772 claims · $493K
Generic: 4,050 claims · $99K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 80 | $69K |
| Dapagliflozin Propanediol | 89 | $64K |
| Empagliflozin | 64 | $56K |
| Semaglutide | 43 | $42K |
| Rivaroxaban | 33 | $30K |
| Dulaglutide | 19 | $29K |
| Fluticasone/Umeclidin/Vilanter | 17 | $23K |
| Linaclotide | 23 | $15K |
| Mirabegron | 14 | $14K |
| Linagliptin | 20 | $13K |
| Evolocumab | 20 | $11K |
| Erenumab-Aooe | 12 | $9,356 |
| Fluticasone/Vilanterol | 18 | $8,038 |
| Empagliflozin/Metformin Hcl | 11 | $6,708 |
| Mesalamine | 14 | $6,235 |
Prescribing Profile
Patient Profile
72
Avg Age
54%
Female
1.40
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About